Related Experiment Video

Updated: Jun 24, 2026

Imaging the Intracellular Trafficking of APP with Photoactivatable GFP
07:55

Imaging the Intracellular Trafficking of APP with Photoactivatable GFP

Published on: October 17, 2015

Pathological synergism between amyloid-beta and apolipoprotein E4--the most prevalent yet understudied genetic risk

Haim Belinson1, Daniel M Michaelson

  • 1Department of Neurobiochemistry, The George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel.

Journal of Alzheimer'S Disease : JAD
|April 14, 2009
PubMed

Insights

Apolipoprotein E4 (apoE4) is a major genetic risk for Alzheimer's disease. This review examines in vivo and in vitro models to understand apoE4's pathological mechanisms and potential therapeutic targets.

Area of Science:

  • Neuroscience
  • Genetics
  • Biochemistry

Background:

  • Apolipoprotein E4 (apoE4) is the primary genetic risk factor for Alzheimer's disease (AD).
  • Understanding the mechanisms behind apoE4's pathological effects is crucial for developing effective AD therapies.
  • Existing research relies on various in vivo and in vitro models to study apoE4's role in AD pathogenesis.

Purpose of the Study:

  • To review and synthesize findings from in vivo and in vitro studies on the mechanisms underlying the pathological phenotype of apolipoprotein E4 (apoE4).
  • To evaluate the utility of transgenic mouse models expressing human apoE alleles in mimicking human apoE4 phenotypes.
  • To explore the impact of apoE4 lipidation state on its biochemical properties and its relevance to in vivo conditions.

Main Methods:

  • Review of in vivo studies using transgenic mice expressing human apoE alleles.
  • Analysis of in vitro studies investigating apoE4's biochemical properties, particularly its lipidation state.
  • Examination of a novel pharmacological in vivo system involving neprilysin inhibition to activate the amyloid cascade in apoE transgenic mice.

Main Results:

  • Transgenic mouse models partially replicate human apoE4-related phenotypes, providing insights into in vivo mechanisms.
  • In vitro studies highlight the influence of apoE4 lipidation on its biochemical behavior, though generalization to in vivo requires caution.
  • The novel pharmacological system offers high spatio-temporal resolution for studying apoE4's in vivo pathological effects within the amyloid cascade.

Conclusions:

  • In vivo and in vitro models are essential for dissecting the complex mechanisms of apoE4 in Alzheimer's disease.
  • Further research integrating findings from diverse models, including novel pharmacological systems, is needed to fully elucidate apoE4's pathological role.
  • Understanding apoE4's mechanisms is key to developing targeted therapeutic strategies for Alzheimer's disease.

More Related Videos

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke09:45

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke

Published on: March 22, 2016

Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections07:28

Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections

Published on: May 19, 2022

Related Concept Videos

Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...